Results 141 to 150 of about 47,170 (292)

Biopharmaceutics [PDF]

, 2020
openaire   +1 more source

Reply to “Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis”

Clinical Pharmacology &Therapeutics, EarlyView.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source

Impact of vigabatrin on risk of relapse of infantile spasms

Epilepsia Open, EarlyView.
Abstract Objective Vigabatrin is an effective treatment for infantile epileptic spasms syndrome (IESS), but relapse remains a clinical challenge. The ideal dose and duration of treatment after response are unknown. We set out to identify treatment‐related predictors of IESS relapse after initial vigabatrin response. Methods We conducted a retrospective
Yaretson I. Carmenate, Hayoung E. Ahn, Haley R. Peters, Hiroki Nariai, Rajsekar R. Rajaraman, Shaun A. Hussain   +5 more
wiley   +1 more source

Advances in recombinant protein bioprocessing: integrating technological innovation and environmental sustainability. [PDF]

Biotechnol Lett
de Freitas Trindade Mota M, Carvalho Pacheco LG, Piedrahita Aguirre CA, de Magalhães Cabral Albuquerque EC.   +3 more
europepmc   +1 more source

Interactions between lactobacillus and yeast: A recent update

Food Biomacromolecules, EarlyView.
Abstract Lactobacillus and yeast are microorganisms widely distributed in nature. Their interactions significantly impact fermentation processes, human health, and medical care. However, there is a lack of a systematic summary of the characteristics of these interactions, and the mechanisms underlying these interactions remain unclear.
Yang Chen, Mengyuan Liu, Mengchen Li, Zhiyun Yue, Yang Mu, Chao Wang, Lusha Xia, Junjun Gao, Mingye Peng, Ran Wang, Mengzhou Zhou   +10 more
wiley   +1 more source

Correction: Modeled reductions in COPD exacerbation rates, mortality, and related medical costs due to increased SITT adoption: PROMETHEUS Italy. [PDF]

Respir Res
Santus P, Oresta B, Finocchiaro D, De Rosa P, Bell J, Caplen M, Carioto J, Bhatt P, Pyenson B, Papi A.   +9 more
europepmc   +1 more source

Conference Report: MSB 2026—International Symposium on Microscale Separations and Bioanalysis With Special Focus on Gel and Polymer Network‐Based Separations

ELECTROPHORESIS, EarlyView.
Andras Guttman
wiley   +1 more source

Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countries. [PDF]

J Pharm Policy Pract
Fowler A, Tantri A, Spencer J, Grieve K, Pendharkar T, Da Silva Duarte Lepez S, Wilsdon T.   +6 more
europepmc   +1 more source

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. [PDF]

J Clin Oncol
Zhao Y, Zhao H, Wang Q, Yang K, Li Y, Fu Z, Yang W, He Z, Wang Y, Ma Y, Yang Y, Fang W, Xiao S, Zhu H, Zhu Y, Zhang L, Huang Y.   +16 more
europepmc   +1 more source

Specific peptide enrichment strategies for neuropsychiatric disorders: From material design to diagnostic applications

Interdisciplinary Medicine, EarlyView.
This review outlines specific peptide enrichment strategies, including metal, magnetic oxides, functional polymers, and antibody‐based approaches, and their mechanisms, highlighting applications in biomarker discovery for major neurological and psychiatric disorders.
Xue Zhang, Yejiao Shi, Minghui Guo, Yang Huang, Yirong Wang, Leping Huang, Helena S. Azevedo, Honggang Hu, Xin Dong   +8 more
wiley   +1 more source